Michael E. Trautmann

TL;DR: Exen atide once weekly resulted in significantly greater improvements in glycaemic control than exenatide given twice a day, with no increased risk of hypoglycaemia and similar reductions in bodyweight.

TL;DR: Exenatide treatment resulted in HbA1c reduction similar to biphasic insulin aspart and provided better postprandial glycaemic control, making it a potential alternative for the treatment of type 2 diabetes.

TL;DR: In this article, the effect of adding exenatide to several oral hypoglycemic drugs in patients with poorly controlled type 2 diabetes has been studied and no one has studied the addition of exenate in clinical trials.

TL;DR: Once weekly exenatide is an important therapeutic option for patients for whom risk of hypoglycaemia, weight loss, and convenience are particular concerns, and this trial aimed to test the hypothesis that improvement in haemoglobin A(1c) (HbA( 1c))) achieved with once weekly exanatide was superior to that achieved with insulin glargine titrated to glucose targets.

TL;DR: Exenatide, an incretin mimetic for the adjunct treatment of type 2 diabetes (DM2), reduced A1C and weight in 30‐week placebo‐controlled trials in patients unable to achieve adequate glycaemic control with sulphonylurea and/or metformin.